ArticleCurrent eye research2009
A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits.
Article in Current eye research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Recruitment of apolipoprotein E facilitates Herpes simplex virus 1 attachment and release.Npj viruses · 2025Article
- Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation.Pharmaceutics · 2020Review
- Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Cellular and molecular life sciences : CMLS · 2015Review
- Peptide therapeutics for treating ocular surface infections.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2014Review
- Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E.PloS one · 2014Article
- The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model.Antiviral research · 2013Article
- A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells.Journal of virology · 2012Article
- High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E.PloS one · 2012Article
- Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?Future microbiology · 2011Review
- A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis.PloS one · 2011Article
- Loss of Down syndrome critical region-1 leads to cholesterol metabolic dysfunction that exaggerates hypercholesterolemia in ApoE-null background.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo compare the antiviral effect of a peptide derived from human apolipoprotein E (1% apoEdp) with 1% trifluorothymidine against HSV-1 thymidine kinase (TK)-positive (HSV-1 McKrae) and with 3% foscarnet against HSV-1 TK-negative (KOS background) in the rabbit eye model of acute HSV-1 epithelial keratitis. MATERIALS AND
methodsTopical treatment began three days post-infection and continued for five days. Rabbits were treated 5 times per day with 1% apoEdp, 1% trifluorothymidine, 3% foscarnet, or PBS. Slit lamp examination was performed on a masked basis from post-infection days 3-10 to determine the severity of epithelial keratitis.
resultsTopical treatment with 1% apoEdp was as effective as 1% trifluorothymidine against TK-positive and 3% foscarnet against TK-negative HSV-1 epithelial keratitis.
conclusionsApoEdp 1% has efficacy for the topical treatment of TK-positive and TK-negative ocular herpes in the rabbit eye model. Thus, apoEdp has the potential to be used for treatment of keratitis caused by TK mutants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.